Heart Failure in Pediatric Oncologic Disease

Neha Bansal, Jyothsna Akam-Venkata, Vivian I. Franco, Steven E. Lipshultz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Children diagnosed with cancer are now living longer, thanks to advances in treatment. However, though cured of cancer, they are at risk for chronic health conditions. Cardiovascular diseases are among the most common cause of morbidity and mortality after recurrence and secondary malignancies. Cardiotoxicity is associated with certain cancer treatments, such as anthracyclines and radiation, and if left undetected or untreated can lead to heart failure, heart transplant, or death. This chapter will provide the latest evidence on risk factors, preventative strategies, screening, and treatment of cardiotoxicity in childhood cancer survivors. Though advances have been made, particularly in prevention by use of the cardioprotectant dexrazoxane, there is still much to be done to find a balance between oncologic efficacy and cardiotoxic late effects.

Original languageEnglish (US)
Title of host publicationHeart Failure in the Child and Young Adult
Subtitle of host publicationFrom Bench to Bedside
PublisherElsevier
Pages331-352
Number of pages22
ISBN (Electronic)9780128026137
ISBN (Print)9780128023938
DOIs
StatePublished - Dec 5 2017
Externally publishedYes

Fingerprint

Heart Failure
Pediatrics
Neoplasms
Dexrazoxane
Anthracyclines
Survivors
Cardiovascular Diseases
Therapeutics
Radiation
Morbidity
Transplants
Recurrence
Mortality
Health
Cardiotoxicity

Keywords

  • Anthracyclines
  • Cardiotoxicity
  • Childhood cancer survivors
  • Heart failure
  • Radiation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bansal, N., Akam-Venkata, J., Franco, V. I., & Lipshultz, S. E. (2017). Heart Failure in Pediatric Oncologic Disease. In Heart Failure in the Child and Young Adult: From Bench to Bedside (pp. 331-352). Elsevier. https://doi.org/10.1016/B978-0-12-802393-8.00032-6

Heart Failure in Pediatric Oncologic Disease. / Bansal, Neha; Akam-Venkata, Jyothsna; Franco, Vivian I.; Lipshultz, Steven E.

Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier, 2017. p. 331-352.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bansal, N, Akam-Venkata, J, Franco, VI & Lipshultz, SE 2017, Heart Failure in Pediatric Oncologic Disease. in Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier, pp. 331-352. https://doi.org/10.1016/B978-0-12-802393-8.00032-6
Bansal N, Akam-Venkata J, Franco VI, Lipshultz SE. Heart Failure in Pediatric Oncologic Disease. In Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier. 2017. p. 331-352 https://doi.org/10.1016/B978-0-12-802393-8.00032-6
Bansal, Neha ; Akam-Venkata, Jyothsna ; Franco, Vivian I. ; Lipshultz, Steven E. / Heart Failure in Pediatric Oncologic Disease. Heart Failure in the Child and Young Adult: From Bench to Bedside. Elsevier, 2017. pp. 331-352
@inbook{9250ea5bcdb84010969dd86469837195,
title = "Heart Failure in Pediatric Oncologic Disease",
abstract = "Children diagnosed with cancer are now living longer, thanks to advances in treatment. However, though cured of cancer, they are at risk for chronic health conditions. Cardiovascular diseases are among the most common cause of morbidity and mortality after recurrence and secondary malignancies. Cardiotoxicity is associated with certain cancer treatments, such as anthracyclines and radiation, and if left undetected or untreated can lead to heart failure, heart transplant, or death. This chapter will provide the latest evidence on risk factors, preventative strategies, screening, and treatment of cardiotoxicity in childhood cancer survivors. Though advances have been made, particularly in prevention by use of the cardioprotectant dexrazoxane, there is still much to be done to find a balance between oncologic efficacy and cardiotoxic late effects.",
keywords = "Anthracyclines, Cardiotoxicity, Childhood cancer survivors, Heart failure, Radiation",
author = "Neha Bansal and Jyothsna Akam-Venkata and Franco, {Vivian I.} and Lipshultz, {Steven E.}",
year = "2017",
month = "12",
day = "5",
doi = "10.1016/B978-0-12-802393-8.00032-6",
language = "English (US)",
isbn = "9780128023938",
pages = "331--352",
booktitle = "Heart Failure in the Child and Young Adult",
publisher = "Elsevier",
address = "Netherlands",

}

TY - CHAP

T1 - Heart Failure in Pediatric Oncologic Disease

AU - Bansal, Neha

AU - Akam-Venkata, Jyothsna

AU - Franco, Vivian I.

AU - Lipshultz, Steven E.

PY - 2017/12/5

Y1 - 2017/12/5

N2 - Children diagnosed with cancer are now living longer, thanks to advances in treatment. However, though cured of cancer, they are at risk for chronic health conditions. Cardiovascular diseases are among the most common cause of morbidity and mortality after recurrence and secondary malignancies. Cardiotoxicity is associated with certain cancer treatments, such as anthracyclines and radiation, and if left undetected or untreated can lead to heart failure, heart transplant, or death. This chapter will provide the latest evidence on risk factors, preventative strategies, screening, and treatment of cardiotoxicity in childhood cancer survivors. Though advances have been made, particularly in prevention by use of the cardioprotectant dexrazoxane, there is still much to be done to find a balance between oncologic efficacy and cardiotoxic late effects.

AB - Children diagnosed with cancer are now living longer, thanks to advances in treatment. However, though cured of cancer, they are at risk for chronic health conditions. Cardiovascular diseases are among the most common cause of morbidity and mortality after recurrence and secondary malignancies. Cardiotoxicity is associated with certain cancer treatments, such as anthracyclines and radiation, and if left undetected or untreated can lead to heart failure, heart transplant, or death. This chapter will provide the latest evidence on risk factors, preventative strategies, screening, and treatment of cardiotoxicity in childhood cancer survivors. Though advances have been made, particularly in prevention by use of the cardioprotectant dexrazoxane, there is still much to be done to find a balance between oncologic efficacy and cardiotoxic late effects.

KW - Anthracyclines

KW - Cardiotoxicity

KW - Childhood cancer survivors

KW - Heart failure

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=85054941892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054941892&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-802393-8.00032-6

DO - 10.1016/B978-0-12-802393-8.00032-6

M3 - Chapter

AN - SCOPUS:85054941892

SN - 9780128023938

SP - 331

EP - 352

BT - Heart Failure in the Child and Young Adult

PB - Elsevier

ER -